Abstract
Objective: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaoundé, Cameroon. Design: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002). Methods: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system. Results: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age. Conclusions: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.
| Original language | English |
|---|---|
| Pages (from-to) | 274-280 |
| Number of pages | 7 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 34 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Nov 1 2003 |
Fingerprint
Keywords
- BDNA
- Cameroon
- HIV-1
- Mother-to-child
- Nevirapine
- Perinatal transmission
- Prevention
ASJC Scopus subject areas
- Virology
- Immunology
Cite this
Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaoundé, Cameroon. / Ayouba, Ahidjo; Tene, Gilbert; Cunin, Patrick; Foupouapouognigni, Yacouba; Menu, Elisabeth; Kfutwah, Anfumbom; Thonnon, Jocelyn; Scarlatti, Gabriella; Monny-Lobé, Marcel; Eteki, Nicole; Kouanfack, Charles; Tardy, Michèle; Leke, Robert; Nkam, Maurice; Nlend, Anne E.; Barré-Sinoussi, Françoise; Martin, Paul M V; Nerrienet, Eric.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 34, No. 3, 01.11.2003, p. 274-280.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaoundé, Cameroon
AU - Ayouba, Ahidjo
AU - Tene, Gilbert
AU - Cunin, Patrick
AU - Foupouapouognigni, Yacouba
AU - Menu, Elisabeth
AU - Kfutwah, Anfumbom
AU - Thonnon, Jocelyn
AU - Scarlatti, Gabriella
AU - Monny-Lobé, Marcel
AU - Eteki, Nicole
AU - Kouanfack, Charles
AU - Tardy, Michèle
AU - Leke, Robert
AU - Nkam, Maurice
AU - Nlend, Anne E.
AU - Barré-Sinoussi, Françoise
AU - Martin, Paul M V
AU - Nerrienet, Eric
PY - 2003/11/1
Y1 - 2003/11/1
N2 - Objective: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaoundé, Cameroon. Design: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002). Methods: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system. Results: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age. Conclusions: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.
AB - Objective: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaoundé, Cameroon. Design: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002). Methods: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system. Results: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age. Conclusions: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.
KW - BDNA
KW - Cameroon
KW - HIV-1
KW - Mother-to-child
KW - Nevirapine
KW - Perinatal transmission
KW - Prevention
UR - http://www.scopus.com/inward/record.url?scp=0242580983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242580983&partnerID=8YFLogxK
U2 - 10.1097/00126334-200311010-00003
DO - 10.1097/00126334-200311010-00003
M3 - Article
VL - 34
SP - 274
EP - 280
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 3
ER -